[Safety and effectiveness of combining clopidogrel and proton pump inhibitors].
Calderón Hernanz
B
B
Pinteño Blanco
M
M
Puigventos Latorre
F
F
Martínez-López
I
I
D001189:Aryl Hydrocarbon Hydroxylases / Q000172:deficiency / Q000378:metabolism*; D001667:Binding, Competitive; D000077144:Clopidogrel; D000075202:Contraindications; D065731:Cytochrome P-450 CYP2C19; D004347:Drug Interactions; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012042:Registries; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D013379:Substrate Specificity; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D006635:Histamine H2 Antagonists; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine